European Journal of Cardiovascular Medicine

Background: Continuous Tretinoin therapy has gained attention for its potential in treating various dermatological conditions, yet its underlying biochemical mechanisms remain insufficiently explored. This study aimed to elucidate the molecular changes induced by continuous retinoid therapy and identify potential biomarkers for treatment response. Methods: A randomized, double-blind, placebo-controlled trial was conducted with 120 participants from a tertiary care hospital. Molecular analyses, including transcriptomics and epigenomics, characterized gene expression and epigenetic modifications. Cytokine profiles were assessed, and clinical responses were rigorously evaluated using validated scoring systems. Data were analyzed using bioinformatics pipelines, statistical tests, and machine learning algorithms. Results: Significant upregulation of the "Keratinocyte Proliferation" pathway indicated cellular turnover enhancement. A moderate rise in the "Inflammation" pathway suggested immunomodulatory effects. IL-6 levels decreased significantly (p = 0.042), suggesting inflammation suppression. Clinical response was markedly higher in the treatment group at Week 4 (p < 0.001) and Week 8 (p = 0.018). Potential biomarkers, such as "Gene A" (p < 0.001), demonstrated predictive capabilities. Conclusion: Continuous Tretinoin therapy induces molecular changes related to enhanced cellular turnover and immunomodulation. IL-6 reduction aligns with observed clinical improvements. The study underscores the potential of biomarkers for treatment stratification and offers insights into the mechanisms of continuous retinoid therapy. Further investigations are warranted to validate and extend these findings.